Alterity Therapeutics Limited
Alterity Therapeutics Limited (ATHE) Stock Overview
Explore Alterity Therapeutics Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
67.4M
P/E Ratio
-2.31
EPS (TTM)
$-1.84
ROE
-2.42%
ATHE Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Alterity Therapeutics Limited (ATHE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 58.95, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.84.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.31 and a market capitalization of 67.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Analyst Recommendations
Price Targets
Company Profile
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
David A. Stamler
10
460 Bourke Street, Melbourne, VIC
2003